Compass Therapeutics (CMPX) Stock Declines as Tovecimig Trial Misses Overall Survival Endpoint Despite Strong PFS and ORR
Compass Therapeutics reported Phase 2/3 COMPANION-002 trial results for tovecimig plus paclitaxel in second-line biliary tract cancer, meeting primary endpoint with 17.1% ORR vs. 5.3% for paclitaxel alone (p=0.031)13.
Key secondary endpoint of median PFS improved to 4.7 months vs. 2.6 months (HR 0.44, p<0.0001)1.
Overall survival did not meet statistical significance due to 54% crossover from control arm to tovecimig; crossover patients had 12.8 months median OS vs. 6.1 months for non-crossover (HR 0.54, p=0.04)1.
CMPX shares were down around 11% in pre-market trading ahead of the data release on April 27, 20262.
Trial enrolled 168 patients randomized 2:
1; company plans BLA submission based on efficacy1.
Sources:
1. https://www.stocktitan.net/sec-filings/CMPX/8-k-compass-therapeutics-inc-reports-material-event-e60495fdf769.html
2. https://stocktwits.com/news-articles/markets/equity/cmpx-stock-retail-buzzing-ahead-of-cancer-drug-trial-update/cZBNZa7Re2t